Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 23, 2015, Pages 7243-7248

  Su, Tung Hung ^a,b,c   Shiau, Chung Wai ^d   Jao, Ping ^a   Liu, Chen Hua ^a,b,c   Liu, Chun Jen ^a,b,c   Tai, Wei Tien ^e,f   Jeng, Yung Ming ^f   Yang, Hung Chih ^b   Tseng, Tai Chung ^g   Huang, Hsiang Po ^h   Cheng, Huei Ru ^a   Chen, Pei Jer ^a,b,c   Chen, Kuen Feng ^e,f   Kao, Jia Horng ^a,b,c,f   Chen, Ding Shinn ^a,b,c,i  

^a Graduate Institute of Clinical Medicine   (Taiwan)

^b Division of Gastroenterology   (Taiwan)

^c Hepatitis Research Center   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e National Center of Excellence for Clinical Trials and Research   (Taiwan)

^f Department of Medical Research ^*  (Taiwan)

^g Taipei Tzu Chi Hospital   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Hepatic stellate cell; Hepatitis B; Liver fibrosis; SHP 1; STAT3

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLIN D1; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAF PROTEIN; SC 1; SORAFENIB; SRC HOMOLOGY PROTEIN TYROSINE PHOSPHATASE 1; STAT3 PROTEIN; THIOACETAMIDE; UNCLASSIFIED DRUG; VANADATE SODIUM; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC HEPATITIS B; CLINICAL ARTICLE; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; EXPERIMENTAL LIVER FIBROSIS; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER BIOPSY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; LIVER CIRRHOSIS;

MUS; RATTUS;

ANIMALS; CELL LINE; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; NIACINAMIDE; PHENYLUREA COMPOUNDS; RATS; STAT3 TRANSCRIPTION FACTOR;

EID: 84983718348     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1507499112     Document Type: Article

References (35)

1. Chen DS (2011) Fighting against viral hepatitis: Lessons from Taiwan. Hepatology 54(2):381-392.
2. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57(1): 167-185, and correction (2013) 58(1):201.
3. Lee YA, Friedman SL (2014) Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C? Antiviral Res 107:23-30.
4. Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med 5(167):167sr161.
5. Su TH, Kao JH, Liu CJ (2014) Molecular mechanism and treatment of viral hepatitisrelated liver fibrosis. Int J Mol Sci 15(6):10578-10604.
6. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6): 1655-1669.
7. Wang Y, et al. (2010) New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 53(1):132-144.
8. Wang H, Lafdil F, Kong X, Gao B (2011) Signal transducer and activator of transcription 3. in liver diseases: A novel therapeutic target. Int J Biol Sci 7(5):536-550.
9. Gao B, Wang H, Lafdil F, Feng D (2012) STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol 57(2):430-441.
10. Nieto N (2006) Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 44(6):1487-1501.
11. Chen KF, et al. (2010) Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16(21):5189-5199.
12. Tai WT, et al. (2011) Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 55(5):1041-1048.
13. Mair M, et al. (2010) Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 138(7):2499-2508.
14. Horiguchi N, et al. (2010) Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology 51(5):1724-1734.
15. Horiguchi N, et al. (2008) Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 134(4):1148-1158.
16. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA (2002) Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35(4):762-771.
17. Wang J, et al. (2009) Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 137(2):713-723.
18. Wilhelm SM, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109.
19. Mejias M, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245-1256.
20. Hennenberg M, et al. (2011) Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 91(2):241-251.
21. Hong F, Chou H, Fiel MI, Friedman SL (2013) Antifibrotic activity of sorafenib in experimental hepatic fibrosis: Refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 58(1):257-264.
22. Thabut D, et al. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54(2):573-585.
23. Chen YL, et al. (2011) Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 53(5):1708-1718.
24. Deng YR, et al. (2013) STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun 46:25-34.
25. Li W, Liang X, Kellendonk C, Poli V, Taub R (2002) STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 277(32):28411-28417.
26. Chen KF, et al. (2011) Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem 46(7):2845-2851.
27. Chen KF, et al. (2012) Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem 55:220-227.
28. Tai WT, et al. (2014) Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology 59(1):190-201.
29. Jiao H, et al. (1996) Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16(12): 6985-6992.
30. Wörns MA, et al. (2009) Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43(5):489-495.
31. Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10(5):470-481.
32. Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives. Drug Saf 36(7):491-503.
33. Sripa B, et al. (2009) Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology 50(4):1273-1281.
34. Lakner AM, Moore CC, Gulledge AA, Schrum LW (2010) Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation. World J Gastroenterol 16(40):5047-5056.
35. Macdonald JM, et al. (2002) Liver cell culture and lineage biology. Methods of Tissue Engineering, eds Atala A, Lanza RP (Academic, New York), pp 155-160.